Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — FY2015 Earnings Presentation
20 slides from Genetic Signatures's earnings presentation, Sep 24, 2015
Slide 1: 2015 Full Year Results Investor Presentation
Genetic Signatures 2015 Full Year Results Investor Presentation
Slide 2: Disclaimer
Disclaimer For personal use only This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australia
Slide 3: Transforming Molecular Diagnostics
Transforming Molecular Diagnostics For personal use only Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (in vitro diagnostics) industry with new technology in infection control. Our primary focus is the development and supply of world leading diagnostic solut
Slide 4: Corporate Summary
Corporate Summary For personal use only Capital Structure ASX Code GSS Shares on Issue 72.9m Market Capitalisation $34m Share Price (at market close 22 September, 2015) $0.49 Cash at June 30 $5.46m Directors & Chief Executive Nick Samaras Non-Executive Chairman John Melki Director & CEO Mike Aicher
Slide 5: 2015 Highlights
2015 Highlights For personal use only Financial Growth Completed oversubscribed Initial Public Offering (IPO) to raise $7.5 million and list on the Australian Securities Exchange (ASX) Achieved greater than $1 million in annual sales revenue for the first time in the history of the Company Dia
Slide 6: 2015 Financial Results
2015 Financial Results For personal use only 30 June 2015 30 June 2014 % Increase $ $ (decrease) Revenue from 1,043,269 684,277 52.5% continuing operations Net loss from (2,659,120) (1,728,487) (53.8)% ordinary activities after tax attributable to shareholders Net loss for the (2,659,120) (1,728,487
Slide 7: FY15 Results Overview
FY15 Results Overview For personal use only 52.5% increase in operating revenue to $1,043,269 A number of significant non-recurring costs were paid in FY2015 and will not have any further impact on cash flow, including $515,000 related to the Company’s IPO and $165,000 for capital equipment requ
Slide 8: 2015 Operational Highlights
2015 Operational Highlights For personal use only Global Market Reach Expansion US subsidiary, Genetic Signatures US Ltd incorporated and its US team expanded Established first European sales channel partnerships with distributors for the regions of Italy and Israel Product Range Expansion Mov
Slide 9: Genetic Signatures: Transforming Global Molecular Diagnostics
For personal use only Genetic Signatures Transforming Global Molecular Diagnostics 9
Slide 10: Company Overview
Company Overview For personal use only Genetic Signatures provides diagnostic solutions for rapid pathogen detection Products already available in Australia and now launching into large global markets, worth US$1.11 billion in 2012 growing to US$1.77 billion in 2017 Proprietary technology driv
Slide 11: Technology – 3Base™
Technology – 3Base™ For personal use only A transformational MDx technology enabling customers to identify a wider array of patient infections Genetic Signatures 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variatio
Slide 12: EasyScreen™ Product Development Pathway
EasyScreen™ Product Development Pathway For personal use only Each product goes through extensive development and beta testing and adheres to rigorous quality management systems & regulatory approach. ISO9001 and ISO13485 certified Already approved by Australian and European regulators 12
Slide 13: Competitive Advantage
Competitive Advantage For personal use only GSS is unique in supplying products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format Uses latest technology compatible with existing equipment (open platform) Ease of use and automation Rapid time to r
Slide 14: Global Growth Strategy
For personal use only Global Growth Strategy 14
Slide 15: FY16 Activities and Growth
FY16 Activities and Growth For personal use only Expansion of EasyScreen™ product range with anticipated commercial release of New Respiratory panel that includes bacterial targets and increases throughput. MRSA assay (otherwise known as 'Golden Staph') Anticipated significant revenue increa
Slide 16: Commercialisation Progress - Australia
Commercialisation Progress - Australia For personal use only • Currently in market with major hospital and pathology group customers Testing for 22 causes of gastroenteritis Testing for 15 causes of viral respiratory disease Next new product in beta testing with customer Dr Tony Radford join
Slide 17: Commercialisation Progress - Europe
Commercialisation Progress - Europe For personal use only Established operations in 2013 Signed Italian distributor and testing with large pathology laboratories, recurrent revenues commencing Signed Israeli distributor agreement Increased European sales channel partnership network by signin
Slide 18: Commercialisation Progress - United States
Commercialisation Progress - United States For personal use only Established operations in 2014 with appointment of key personnel Anticipate entering market in 2015In FY15 GSS achieved first regulatory step towards full product suite commercialisation in the US with receipt of a United States Fo
Slide 19: Summary
Summary For personal use only EasyScreen™ Respiratory & Enteric Pathogen Detection Kits provide faster & more accurate screening for viral, bacterial and protozoan pathogens – tests are processed in hours instead of days, with fewer false positives and negatives The 3Base™ platform and products
Slide 20: Contact
For personal use only Contact: John Melki Chief Executive Officer john@geneticsignatures.com www.geneticsignatures.com 20